Drugs / HYNRCS-Allo inj
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03214146 | Feb 2017 → Mar 2019 | amyotrophic lateral sclerosis | Hanyang University Seoul Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HYNRCS-Allo inj | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03214146 ↗ |
| Known as | HYNRCS-Allo-ALS-02 inj | “HLA-haplo matched Allogenic Bone Marrow Derived stem cells("HYNRCS-Allo-ALS-02 inj")” NCT03214146 ↗ |
| Modality | Cell therapy | “Allogenic Bone Marrow Derived stem cells” NCT03214146 ↗ |
| Route | Intrathecal | “by intrathecal administration” NCT03214146 ↗ |